Testing effectiveness (Phase 2)Looking for participantsNCT04758975
What this trial is testing
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
Paolo Ghia 55